Sage Journals: Discover world-class research

Abstract

Health is a global concern. The need for a globalized response is evident in the pharmaceutical industry. Although pharmaceutical products are developed and marketed internationally, they are currently regulated only at national level. The pharmaceutical agencies regulate medical products in a globalized environment. However, national regulations can create significant barriers to pharmaceutical availability. We must formulate our laws with a global focus. The globalization of regulation weakens national sovereignty but empowers transnational epistemic networks. For this reasons the pharmaceutical agencies are involved in several bilateral and multilateral cooperation activities with international partners. International cooperation is a key area of work for the agencies. This process will benefit of advancement in global governance and progress toward supranationalism. The internationalization of the pharmaceutical industry, highly globalized, involves changes in policies, lifestyle and culture, and has altered drug research, production, and regulation.

Keywords

Pharmaceutical industry globalization regulations ICH governance governments pharmaceutical agencies products liability pharmaceuticals inspections

Get full access to this article

View all access options for this article.

References

jlvalver@ugr.es.

Koenig-Archibugi

Mathias

(2011) Global governance. In: Michie

Jonathan

, (ed.) The handbook of Globalisation. Edward Elgar Publishing Ltd, Cheltenham, pp. 393-406.

EFPIA. How a Strong Pharmaceutical Chapter in TTIP will Benefit the EU. http://www.efpia.eu/topics/industry-economy/trade/ttip.

The Future of Drug Safety: Promoting and Protecting the Health of the Public. Committee on the Assessment of the US Drug Safety System, Baciu

Alina

, Stratton

Kathleen

, Burke

Sheila P.

, Editors. This PDF is available from the National Academies Press at: http://www.nap.edu/catalog/11750.html.

Innovation.org (2007) Drug discovery and development: Understanding the R&D process. Washington DC: Pharmaceutical Research and Manufacturers of America. http://www.innovation.org/drug_discovery/objects/pdf/RD_Brochure.pdf/.

Grabowski

H.G.

, DiMasi

J.A.

and Long

, The Roles of Patents and Research and Development Incentives In Biopharmaceutical Innovation, Health Aff. 34(2) (2015), 302-310.

Authorities in Australia, Brazil, Canada, China, Japan, Korea, Mexico, New Zealand, Nigeria, South Africa and the United States. The European Commission is also a member and the World Health Organisation (WHO) is an observer.

It includes the following participants: the EMA and all EU member States, the European EDQM, the U.S. FDA, the Australian Therapeutic Goods Administration (TGA) and WHO.

https://www.pda.org/pda-letter-portal/archives/full-article/gmp-oversight-of-medicines-manufacturers-in-the-european-union.

10.

The Working Procedures of the Pharmacopoeia Discussion Group (PDG) for further information. See more at: https://www.edqm.eu/en/international-harmonisation-614.html#sthash.P8uSO514.dpuf.

The globalization of medicines as a challenge for governments

Abstract

Keywords

Get full access to this article

References